mdprostate

mediaire

mdprostate enables AI-based evaluation of prostate MRIs through automatic identification and classification of lesions according to PI-RADS 2.1. The output includes comprehensive quantitative reports and visual overlays directly integrated into the PACS system, with the lesions marked on a sector map.

The automated graphical presentation, including the overview of prostate volume, lesion size, ADC values, and optionally PSA density, accelerates and simplifies the classification.

Product specifications

Information source: Vendor
Last updated: Aug. 23, 2023

General
Product name	mdprostate
Company	mediaire
Subspeciality	Abdomen
Modality	MR
Disease targeted	Prostate cancer
Key-features	Automated segmentation of the prostate with volume calculation, detection and evaluation of suspicious lesions, classification of lesions according to PI-RADS 2.1 and determination of relevant parameters (e.g., extent, EPE, index lesion), PSA density.
Suggested use	During: interactive decision support (shows abnormalities/results only on demand), report suggestion After: diagnosis verification
Data characteristics
Population	Patients suspected of (initial diagnosis), or diagnosed with (follow-up) prostate cancer.
Input	1.5T or 3T MRI systems. Sequences included in the evaluation: T2-weighted, DWI, ADC
Input format	DICOM
Output	PDF report with: - Tabular overview of detected lesions and their analysis - Prostate volume (optional PSA density) - Slices of the most significant lesions - Schematic representation of detected lesions ≥ PI-RADS 3 Color-coded segmentation overlays
Output format	PDF, DICOM-PDF, browser-based platform, CSV-Export file
Technology
Integration	Integration in standard reading environment (PACS), Integration RIS (Radiological Information System), Integration via AI marketplace or distribution platform, Stand-alone third party application
Deployment	Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based
Trigger for analysis	Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time	2 - 3 minutes
Certification
CE	Certified, Class IIb , MDR
FDA	No or not yet
Market presence
On market since	08-2023
Distribution channels
Countries present (clinical, non-research use)	11
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model	Pay-per-use
Based on	Number of analyses
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers